Sale Of Royalty Rights was Pyxis Oncology’s largest product and service line in fiscal 2025, bringing in $11.04M of $13.86M (80%).
| Product and Service | FY 2024 | FY 2025 |
|---|---|---|
| Sale Of Royalty Rights | $8.00M | $11.04M |
| Royalty Revenues | $8.15M | — |
| Milestone Revenue | — | $2.82M |
| Total | $16.15M | $13.86M |
Pyxis Oncology brought in $13.86M from its two product and service lines in fiscal 2025, the year ended December 31, 2025. Pyxis Oncology regrouped these lines after fiscal 2024, so the total does not compare directly with that year's $16.15M. Sale Of Royalty Rights was the largest at $11.04M (79.7%), ahead of Milestone Revenue at $2.82M (20.3%).
Pyxis Oncology began breaking out Milestone Revenue in fiscal 2025, when it brought in $2.82M. Pyxis Oncology stopped reporting Royalty Revenues as a separate line after fiscal 2024, when it brought in $8.15M.
Pyxis Oncology (PYXS) reports its revenue by product and service. In fiscal 2025, Sale Of Royalty Rights was its largest product and service line, bringing in $11.04M (79.7% of the total), followed by Milestone Revenue at $2.82M (20.3%).
Sale Of Royalty Rights was Pyxis Oncology's largest product and service line in fiscal 2025, bringing in $11.04M, or 79.7% of the $13.86M total across its two product and service lines.
Every figure comes from Pyxis Oncology's annual financial filings, as reported. Each line keeps the name Pyxis Oncology gives it, and years follow its fiscal calendar.
Pyxis Oncology's revenue by product and service goes back to fiscal 2024, with figures through fiscal 2025. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.